HIV感染者の非感染性合併症に関する検討
キーワード：HIV、高齢化、非感染性合併症
2017.04～2019.06.
| 村田 昌之（むらたまさゆき） | データ更新日：2024.04.09 |
主な研究テーマ
SCCmec type IV MRSAの分子疫学的解析
キーワード：MRSA、市中感染型、SCCmec IV
2014.04.
キーワード：MRSA、市中感染型、SCCmec IV
2014.04.
B型慢性活動性肝炎に対するPEG-IFNα-２a単独療法の有効性および安全性に関する検討
キーワード：B型肝炎、ペグインターフェロン
2013.09～2018.09.
キーワード：B型肝炎、ペグインターフェロン
2013.09～2018.09.
HCV/HIV重複感染
キーワード：C型慢性肝炎、HIV感染症
2010.04.
キーワード：C型慢性肝炎、HIV感染症
2010.04.
HBV/HIV重複感染
キーワード：B型肝炎ウイルス、ヒト免疫不全ウイルス
2010.04.
キーワード：B型肝炎ウイルス、ヒト免疫不全ウイルス
2010.04.
医療関連感染症
キーワード：院内感染、MRSA
2004.04.
キーワード：院内感染、MRSA
2004.04.
HIV感染症の病因
キーワード：ヒト免疫不全ウイルス、後天性免疫不全症候群
2004.04.
キーワード：ヒト免疫不全ウイルス、後天性免疫不全症候群
2004.04.
研究業績
主要原著論文
| 1. | Fujiko Mitsumoto-Kaseida, Masayuki Murata, Koji Takayama, Kazuhiro Toyoda, Eiichi Ogawa, Norihiro Furusyo, Jun Hayashi, Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients, Journal of Infection and Chemotherapy, 10.1016/j.jiac.2019.06.003, 26, 1, 28-32, 2020.01, [URL], Occult hepatitis B virus (HBV) infection (OBI) is hepatitis B surface antigen (HBsAg) negative but with detectable HBV DNA. Although HIV infection has been reported to be a risk factor for OBI, the prevalence and clinical features of OBI in Japanese HIV infected patients have not been documented. This retrospective, single-center study was conducted to determine the prevalence and characteristic of OBI in Japanese antiretroviral therapy (ART) naïve HIV infected patients. OBI was defined as the presence of serum HBV DNA but without detectable HBsAg. Of the 147 ART naïve HIV infected patients, OBI was detected in 9 (6.1%) patients; 2 (4.3%) of 47 with both anti-HBs and anti-HBc positive, 6 (27.3%) of 22 with anti-HBc alone, and 1 (2.0%) of 50 with both anti-HBs and anti-HBc negative. The mean HBV DNA level was low at 28.7 ± 18.2 IU/mL. The proportion of OBI patients with anti-HBc alone was significantly higher than that of non-OBI patients (66.7% vs 14.5%, P = 0.001). In addition, the prevalence of AIDS (acquired immunodeficiency syndrome)-defining illnesses in the OBI group was significantly higher than in the non-OBI group (77.8% vs 35.5%, P = 0.001). No significant difference was found in the CD4 count or alanine aminotransferase levels of these two groups. This is the first study to reveal the prevalence and clinical features of OBI in Japanese HIV-infected patients. The persistence of anti-HBc alone and AIDS-defining illnesses were associated with the occurrence of OBI in these patients.. |
| 2. | Fujiko Mitsumoto, Masayuki Murata, kazuya Ura, Koji Takayama, Satoshi Hiramine, Motohiro Shimizu, Toyoda K, Eiichi Ogawa, Norihiro Furusyo, Jun Hayashi, The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients, JOURNAL OF INFECTION AND CHEMOTHERAPY, 10.1016/j.jiac.2014.12.003, 21, 3-4, 264-271, 2015.04. |
| 3. | 村田 昌之, 古庄 憲浩, 小川 栄一, 光本 富士子, 平峯 智, 池崎 裕昭, 高山 耕治, 志水 元洋, 豊田 一弘, 貝沼 茂三郎, 林 純, A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy, 10.1016/j.jiac.2013.11.006., 20, 5, 320-324, 2014.05. |
| 4. | 村田 昌之, 古庄 憲浩, 小川 栄一, 光本 富士子, 平峯 智, 池崎 裕昭, 高山 耕治, 志水 元洋, 豊田 一弘, 貝沼 茂三郎, 林 純, A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy., doi: 10.1016/j.jiac.2013.11.006., 2013.11, In Japan, the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection of some patients with hemophilia was caused by the transfusion of imported blood products, such as unheated coagulation factor. With the development of antiretroviral therapy (ART) for HIV, chronic HCV infection has become a major cause of liver disease and mortality for hemophiliac patients coinfected with HCV/HIV. Data is limited regarding the efficacy and safety of antiviral therapy with the HCV protease inhibitor telaprevir (TVR) in combination with pegylated interferon-α (PegIFN-α) and ribavirin (RBV) for hemophilia patients coinfected with HCV/HIV. We report a case of a Japanese patient with hemophilia and HCV/HIV coinfection who had partial response to prior to PegIFN-α and RBV therapy. This is the first published report of 24-week TVR-based triple therapy for a hemophilia patient coinfected with HCV/HIV. The patient had HCV genotype 1a infection with a high viral load. His single-nucleotide polymorphism of the interleukin 28B (rs8099917) gene was the TT major allele. He presented with undetectable HIV RNA and a high CD4(+) T cell counts by taking ART including tenofovir, emtricitabine and raltegravir. He was again treated for HCV with TVR plus PegIFN-α2b and RBV for the first 12 weeks, followed by the continuation of PegIFN-α2b and RBV for 12 additional weeks while continuing ART. He had rapid virological response and achieved sustained virological response with the 24-week treatment. No serious adverse events such as skin rash, severe anemia or exacerbated bleeding tendency were observed, only a mild headache. No dose adjustment was necessary when tenofovir and raltegravir were used in combined with TVR, and no HIV breakthrough was observed. TVR-based triple therapy with ART could can an effective treatment for hemophilia patients coinfected with HCV (genotype 1)/HIV regardless of prior response. TVR can be used in combination with tenofovir, emtricitabine and raltegravir for patients with hemophilia. Furthermore, patients with undetectable HCV RNA at week 4 could be successfully treated with a 24-week regimen.. |
| 5. | Murata M, Furusyo N, Unno M, Ogawa E, Toyoda K, Taniai H, Ohnishi H, Hayashi J., Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients., World J Gastroenterol. 2011 Jun 28;17(24):2945-52., 17, 24, 2945-52, 2011.06, AIM: To analyze the association between the emergence of tyrosine-methionine-asparatate-asparatate (YMDD) mutants (reverse transcription; rtM204I/V) and deterioration of liver function during long-term lamivudine treatment of Japanese patients with chronic hepatitis B virus (HBV) infection. METHODS: The data of 61 consecutive Japanese patients with chronic hepatitis B who underwent continuous lamivudine treatment for more than 24 mo and had a virological response were analyzed. Analysis of YMDD mutants was done by real-time polymerase chain reaction with LightCycler probe hybridization assay for up to 90 mo (mean, 50.8 mo; range, 24-90 mo). RESULTS: A mixed mutant-type (YMDD + tyrosine-isoleucine-asparatate-asparatate: YIDD or tyrosine-valine-asparatate-asparatate: YVDD) or a mutant-type (YIDD or YVDD) were found in 57.4% of 61 patients at 1 year, 78.7% of 61 patients at 2 years, 79.6% of 49 patients at 3 years, 70.5% of 34 patients at 4 years, 68.4% of 19 patients at 5 years, 57.1% of 14 patients at 6 years, and 33.3% of 6 patients at 7 years. Of the 61 patients, 56 (92%) had mixed mutant- or a mutant-type. Only 5 (8%) had no mutants at each observation point. Virological breakthrough was found in 26 (46.4%) of 56 patients with YMDD mutants, 20 of whom had a hepatitis flare-up: the remaining 30 (53.6%) had neither a virological breakthrough nor a flare-up. All 20 patients who developed a hepatitis flare-up had a biochemical and virological response after adefovir was added to the lamivudine treatment. CONCLUSION: Our results suggest that it is possible to continue lamivudine treatment, even after the emergence of YMDD mutants, up to the time that the patients develop a hepatitis flare-up.. |
主要学会発表等
学会活動
学会大会・会議・シンポジウム等における役割
2020.02.21～2020.02.22, 第20回日本病院総合診療医学会 学術総会, 副大会長.
2019.09.14～2019.09.15, 第19回日本病院総合診療医学会 学術総会, 座長.
2017.01.21～2017.01.21, 日本内科学会九州支部主催 第316回九州地方会, 座長（Chairmanship）.
2016.11.24～2016.11.26, 第86回日本感染症学会西日本地方会学術集会, 座長（Chairmanship）.
2016.01.16～2016.01.16, 日本内科学会九州支部主催 第312回九州地方会, 座長（Chairmanship）.
2015.05.15～2015.05.15, 第16回福岡HIV感染症治療研究会, 座長（Chairmanship）.
2015.04.16～2015.04.17, 第89回日本感染症学会総会, 座長（Chairmanship）.
2015.02.27～2015.02.28, 第10回日本病院総合診療医学会学術総会, 座長（Chairmanship）.
2014.09.19～2014.09.20, 第9回日本病院総合診療医学会学術総会, 座長（Chairmanship）.
2014.08.05～2014.08.05, 第21回福岡ICT交流会, 座長（Chairmanship）.
2014.06.18～2014.06.20, 第88回日本感染症学会学術集会/第62回日本化学療法学会総会 合同学会, 座長（Chairmanship）.
2013.11.15～2013.11.15, 第14回福岡HIV感染症治療研究会, 座長（Chairmanship）.
2013.01.12～2013.01.12, 日本内科学会九州支部主催 第300回九州地方会, 座長（Chairmanship）.
2012.04.25～2012.04.26, 第86回日本感染症学会総会 , 座長（Chairmanship）.
2012.01.28～2012.01.28, 第296回日本内科学会九州支部主催九州地方会, 座長（Chairmanship）.
2011.02.03～2011.02.04, 第2回日本病院総合診療医学会学術総会, 座長（Chairmanship）.
2010.05.14～2010.05.14, 第7回福岡HIV感染症治療研究会, 座長（Chairmanship）.
2010.02.05～2010.02.06, 第1回日本病院総合診療医学会学術総会, 座長（Chairmanship）.
2010.01.30～2010.01.30, 第288回日本内科学会 九州地方会, 座長（Chairmanship）.
2009.11.19～2009.11.20, 第79回日本感染症学会西日本地方会学術集会, 座長（Chairmanship）.
2009.05.15～2009.05.15, 第5回福岡HIV感染症治療研究会, 座長（Chairmanship）.
2008.10.24～2008.10.24, 福岡HIV感染症治療研究会, 座長（Chairmanship）.
2007.11～2007.11, 第10回日本補完代替医療学会学術集会, 座長（Chairmanship）.
2012.01.19～2012.01.20, 平成23年度院内感染対策講習会, 講習会事務責任者.
2011.03.12～2011.03.12, 日本医療マネージメント学会 第11回福岡支部学術集会, シンポジウム責任者.
2011.01.29～2011.01.29, 第292回日本内科学会九州支部主催九州地方会, 事務局長.
2009.02.28～2009.03.01, 第17回日本総合診療医学会学術集会, 学術集会事務局長.
学術論文等の審査
| 年度 | 外国語雑誌査読論文数 | 日本語雑誌査読論文数 | 国際会議録査読論文数 | 国内会議録査読論文数 | 合計 |
|---|---|---|---|---|---|
| 2022年度 | 3 | 3 | |||
| 2021年度 | 3 | 3 | |||
| 2020年度 | 4 | 4 | |||
| 2019年度 | 3 | 3 | |||
| 2018年度 | 1 | 1 | |||
| 2017年度 | 1 | 1 | |||
| 2016年度 | 2 | 2 | |||
| 2015年度 | 2 | 2 | |||
| 2011年度 | 1 | 1 | |||
| 2007年度 | 1 | 1 | |||
| 2006年度 | 1 | 1 |
その他の研究活動
本データベースの内容を無断転載することを禁止します。